Nov162021UncategorizedCategory: UncategorizedBy Charlotte Maddalena16 November 2021 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Two new projects supported by our Endowment FundNextNext post:Newsletter December 2021Related PostsFirst patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®22 June 2022ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspension9 June 2022Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer7 June 2022ORPHELIA reports positive results of the bioequivalence study of KIMOZO® (oral suspension of temozolomide)31 May 2022ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy11 May 2022No title28 April 2022
First patient included under the French Early Access Program granted to ORPHELIA Pharma for KIMOZO®22 June 2022
ORPHELIA Pharma and Gustave Roussy announce the publication of the scientific work related to the first temozolomide oral suspension9 June 2022
Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer7 June 2022
ORPHELIA reports positive results of the bioequivalence study of KIMOZO® (oral suspension of temozolomide)31 May 2022
ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy11 May 2022
